On August 9, 2023, Decibel Therapeutics, Inc. (the ?Company?), entered into an Agreement and Plan of Merger (the ?Merger Agreement?), dated as of August 8, 2023, with Regeneron Pharmaceuticals, Inc. (?Parent?), and Symphony Acquisition Sub, Inc. a wholly owned subsidiary of Parent (?Purchaser?). In accordance with the terms of the Merger Agreement, each of William Carson, Alison Finger, Matthew Kapusta, Kevin McLaughlin, Saraswathy Nochur and Laurence Reid resigned from his or her respective positions as a member of the Company?s board of directors and all committees thereof, effective as of the Effective Time and Nouhad Husseini, the sole director of the Purchaser immediately prior to the Effective Time, became the sole director of the Company, in each case, as of the Effective Time. The director resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company?s operations, policies or practices.

Following the Effective Time, the officers of the Company are as follows: Nouhad Husseini, Managing Director, Robert E. Landry, Chief Financial Officer, Joseph J. LaRosa, Secretary, and Leonard N. Brooks, Treasurer.